Results 31 to 40 of about 825,198 (275)
The ANXA2/S100A10 Complex—Regulation of the Oncogenic Plasminogen Receptor
Biomolecules, 2021 The generation of the serine protease plasmin is initiated by the binding of its zymogenic precursor, plasminogen, to cell surface receptors.
Alamelu G. Bharadwaj +2 more
doaj +1 more source
Mutations and amplification of oncogenes in endometrial cancer [PDF]
, 1999 Alterations in oncogenes are critical steps in the development of endometrial cancer. To investigate the potential clinical relevance of the amplification of the oncogenes c-erbB2, c-myc, and int-2 and the mutation of K-ras in endometrial cancer, 112 ...
An, Han-Xiang +5 more
core +1 more source
Applied Sciences, 2021 Gene therapy aims to silence an oncogene through RNA interference, or replace an abnormal tumour suppressor via gene augmentation. In this study, we intended RNA interference for PRKCA oncogene and gene augmentation for PTEN tumour suppressor with a view
Nabilah Ibnat +2 more
doaj +1 more source
The Nefarious Nexus of Noncoding RNAs in Cancer [PDF]
, 2018 The past decade has witnessed enormous progress, which has seen the noncoding RNAs (ncRNAs) turn from the so called dark matter RNA to critical functional molecules, influencing most physiological processes in development and disease contexts.
Anastasiadou, Eleni +3 more
core +1 more source
Protein palmitoylation in cancer: molecular functions and therapeutic potential
Molecular Oncology, 2023 Protein S‐palmitoylation (hereinafter referred to as protein palmitoylation) is a reversible lipid posttranslational modification catalyzed by the zinc finger DHHC‐type containing (ZDHHC) protein family.
Binhui Zhou +3 more
doaj +1 more source
miRNAs link metabolic reprogramming to oncogenesis [PDF]
, 2013 The most profound biochemical phenotype of cancer cells is their ability to metabolize glucose to lactate, even under aerobic conditions. This alternative metabolic circuitry is sufficient to support the biosynthetic and energy requirements for cancer ...
Hatziapostolou, M +2 more
core +1 more source
Targeting mTOR for cancer therapy
Journal of Hematology & Oncology, 2019 Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua +5 more
doaj +1 more source
Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein [PDF]
, 2012 The oncogenic MUC1-C subunit is aberrantly overexpressed in most human breast cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non- malignant MCF-10A cells with epidermal growth factor (EGF) or ...
Jin, Caining +4 more
core +1 more source
Nature CommunicationsMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to treat KRAS ...
Panayiotis Anastasiou +15 more
doaj +1 more source
Structural basis for the assembly of the Ragulator-Rag GTPase complex
Nature Communications, 2017 mTORC1 activity is controlled through Rag GTPases, which are anchored to the lysosome through the Ragulator. Here, the authors give molecular insights into Ragulator-Rag GTPase assembly and present the crystal structures of the Ragulator alone and in ...
Ryo Yonehara +12 more
doaj +1 more source